Among them, the FDA approved alpelisib, a PI3K inhibitor, and everolimus, an mTOR inhibitor for the treatment of advanced HR+ /HER2− BC, but they have not yet been approved for advanced HER2+ BC. This evidence concerns the gene ERBB2 and breast cancer.